Our Research Methodology
Our investigation began with a complete pass over Coby’s website, focusing on pricing, coverage, and governance. We cataloged the full pricing matrices for compounded semaglutide and compounded tirzepatide, including monthly options and multi-month bundles that lower the effective monthly rate. We verified that medication, injection supplies, and shipping are included in the listed prices and that no membership is required to purchase. We also confirmed the policy pages and footer disclosures, which clarify that Coby functions as a marketplace connecting patients to independent clinicians and pharmacies rather than dispensing medications itself. Prices are posted publicly on the product pages for both drugs, reducing quote chasing.
Testing their onboarding process revealed a lightweight, approximately 3 minute online questionnaire, followed by clinician review. We confirmed Coby’s stated review target of 24 to 48 hours after submission and noted that approval triggers a prescription routed to a partner pharmacy for fulfillment. We documented the presence of pre-authorization card holds during order submission with release on denial, and we confirmed that optional subscriptions can be used but are not required, with a 30 day cancellation window to avoid the next cycle. These operational details align with current telehealth norms for GLP-1 programs and set clear expectations for patients planning first shipments.
Our evaluation of service quality combined channel review and external outcome checks. We verified accessible support paths via a posted phone number, email address, and a portal workflow that directs clinical questions to the care team. We then monitored public feedback trends for confirmation of speed and reliability. Across recent reviews we observed frequent references to quick approvals and shipping within a few days, with scattered reports of carrier related delays that were resolved through customer service follow up. This triangulation supports the platform’s emphasis on responsiveness while acknowledging that fulfillment is ultimately executed by partner pharmacies.
During our analysis of policies and fulfillment, we confirmed strict refund rules: no refunds after shipment, a $50 clinical fee on successful cancellations before pharmacy ordering, and the presence of card pre-authorization holds. We also confirmed that Coby’s safety and policy pages clearly state compounded GLP-1 medications are not FDA approved and that prescribing is at the clinician’s discretion. Coverage is broad but not universal, with GLP-1 programs unavailable in Arkansas, Louisiana, Mississippi, and New Mexico. In total, the disclosures are consistent with industry expectations for a marketplace model that coordinates licensed providers and pharmacies while keeping pricing and fulfillment timelines visible to prospective patients.







